Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by gudisgoodon Apr 29, 2023 8:08am
189 Views
Post# 35420624

Current Valuation ($500M)

Current Valuation ($500M)Excluding increases in working capital (which are supposed to stabilize right about now), we're looking at a 10% operational cash flow return (2022) on the current market cap. We also have $260 million - that is to say, more than 50%! - of the current market cap in net cash, marketable securities and financial assets.

While 2023 may see a temporary setback for cash flows - although I don't think it will be a major one, since in the annual report they specifically say strong cash flows will continue - I believe the long-term trajectory for cash flows is UP from current levels. 60% of the innovative portfolio is still in the promotional phase and we likely have many launches coming up in 2024 (both innovative and BGx).

In addition to the current portfolio and pipeline, we still have plenty of capital left to allocate. It's been quiet on this front -- when will they find new deals? We know that in addition to building the pipeline and acquiring suitable products that immediately generate cash, they're looking for solutions to scale both Canada and Mexico.
<< Previous
Bullboard Posts
Next >>